Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Osteoporosis International

• Publication date

  2019-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00198-018-4794-0PMID 30603840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors

  2018cited by this paper
• Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV

  2018cited by this paper
• Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial

  2018cited by this paper
• The Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk

  2018cited by this paper
• High Prevalence of Sarcopenia in HIV-Infected Individuals

  2018cited by this paper
• Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

  2017cited by this paper
• Bone Loss in HIV Infection

  2017cited by this paper
• Bone health in HIV and hepatitis B or C infections

  2017cited by this paper
• Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s

  2017cited by this paper
• An increased rate of fracture occurs a decade earlier in HIV+ compared with HIV− men

  2017cited by this paper
• Changes in bone turnover markers with HIV seroconversion and ART initiation

  2017cited by this paper
• Trabecular bone score (TBS) is associated with sub-clinical vertebral fractures in HIV-infected patients

  2017cited by this paper
• Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons

  2017cited by this paper
• Novel imaging modalities for the comparison of bone microarchitecture among HIV+ patients with and without fractures: a pilot study

  2017cited by this paper
• Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide

  2017cited by this paper
• Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients

  2017cited by this paper
• Osteoporosis in postmenopausal women living with HIV.

  2017cited by this paper
• Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health

  2017cited by this paper
• Frailty in HIV infected people: a new risk factor for bone mineral density loss

  2017cited by this paper
• Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine

  2017cited by this paper
• A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX

  2016cited by this paper
• Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients

  2016cited by this paper
• Fracture Prediction With Modified-FRAX in Older HIV-Infected and Uninfected Men

  2016cited by this paper
• Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection

  2016cited by this paper
• Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population

  2016cited by this paper
• Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study

  2016cited by this paper
• Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients

  2016cited by this paper
• A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.

  2016cited by this paper
• Bone Loss Among Women Living With HIV

  2016cited by this paper
• The protease inhibitors and HIV-associated bone loss

  2016cited by this paper
• HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy

  2016cited by this paper
• HIV infection and bone disease

  2016cited by this paper
• Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir

  2016cited by this paper
• Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection

  2016cited by this paper
• Which HIV patients should be screened for osteoporosis: an international perspective

  2016cited by this paper
• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

  2016cited by this paper
• Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients

  2016cited by this paper
• Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?

  2016cited by this paper
• Role of T cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss

  2015cited by this paper
• Skeletal health in adults with HIV infection.

  2015cited by this paper
• Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

  2015cited by this paper
• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

  2015cited by this paper
• Vitamin D, osteoprotegerin/receptor activator of nuclear factor‐kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV‐infected patients with reduced bone mineral density

  2015cited by this paper
• Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation

  2015cited by this paper
• Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

  2015cited by this paper
• Recommendations for evaluation and management of bone disease in HIV.

  2015cited by this paper
• Teriparatide treatment of osteoporosis in an HIV-infected man: a case report and literature review.

  2015cited by this paper
• Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection

  2014cited by this paper
• Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy

  2014cited by this paper
• Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study

  2014cited by this paper
• Change in Vitamin D Levels and Risk of Severe Vitamin D Deficiency over 48 Weeks among HIV-1-Infected, Treatment-Naive Adults Receiving Rilpivirine or Efavirenz in a Phase III Trial (Echo)

  2014cited by this paper
• Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings

  2014cited by this paper
• Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco

  2011cited by this paper
• Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

  2011cited by this paper
• Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.

  2011cited by this paper
• FRAX® assessment of osteoporotic fracture probability in Switzerland

  2010cited by this paper
• Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study

  2010cited by this paper
• Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats

  2010cited by this paper
• Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.

  2009cited by this paper
• Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

  2009cited by this paper
• The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis

  2002cited by this paper
• Changes in Bone Mineral Density with Age in Men and Women: A Longitudinal Study

  2002cited by this paper
• HIV und Aids

  1998cited by this paper

• Low Bone Mineral Density and Associated Factors Among People Living With HIV in Kerman, Iran: A Cross-Sectional Study in 2021–2022

  2025cites this paper
• Narrative Review on Parathyroid Gland Disorders in Individuals Living with HIV: An Update

  2025cites this paper
• A multivariate analysis of the impact of HIV infection on the risk of osteoporosis based on the NHANES database

  2025cites this paper
• Rheumatological mimickers of HIV infection. Part 1: involvement of the musculoskeletal system

  2025cites this paper
• Narrative Review on the Management of Neck of Femur Fractures in People Living with HIV: Challenges, Complications, and Long-Term Outcomes

  2025cites this paper
• Optimizing bone health in people living with HIV: insights from a network meta-analysis of randomized controlled trials

  2025influential citation
• Bone Loss and Fractures in Post-Menopausal Women Living with HIV: A Narrative Review

  2024cites this paper
• In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa

  2024cites this paper
• Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America.

  2024cites this paper
• Bone Tissue Changes in Individuals Living with HIV/AIDS: The Importance of a Hierarchical Approach in Investigating Bone Fragility

  2024cites this paper
• Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study

  2023cites this paper
• Grip strength cut-points from the Swiss DO-HEALTH population

  2023cites this paper
• Bone Health in People Living with HIV/AIDS: An Update of Where We Are and Potential Future Strategies

  2023cites this paper
• Lower bone density and microarchitecture alterations in HIV‐infected Brazilian men aged 50 years and older are associated with estradiol levels

  2022cites this paper
• Osteoporosis and HIV Infection

  2022cites this paper
• Vitamin D and Calcium Supplementation Reverses Tenofovir-Caused Bone Mineral Density Loss in People Taking ART or PrEP: A Systematic Review and Meta-Analysis

  2022cites this paper
• Frequency of Osteoporosis/Osteopenia, Vitamin D Levels and Associated Risk Factors in HIV/AIDS Patients

  2022cites this paper
• The evaluation of risk factors related to reduced bone mineral density in young people living with HIV

  2022cites this paper
• Manifestations rhumatologiques de l’infection par les virus de l’immunodéficience humaine

  2021cites this paper
• Vitamin D and Primary Ciliary Dyskinesia: A Topic to Be Further Explored

  2021cites this paper
• Effects of exercise training on bone mineral density in adults living with HIV: a retrospective study

  2021cites this paper
• Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy

  2021cites this paper
• Human immunodeficiency virus and osteoporosis

  2021cites this paper
• People living with HIV and fracture risk

  2020cites this paper
• Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy

  2020cites this paper
• Discovery and development of berberine derivatives as stimulants of osteoblast differentiation.

  2020cites this paper
• Human immunodeficiency virus infection (HIV)–associated rheumatic manifestations in thepre- and post-HAART eras

  2020cites this paper
• Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America.

  2020cites this paper
• Current state-of-the-art pharmacotherapy for the management of hepatitis B infection

  2019cites this paper
• Special Topics in the Care of Older People with HIV

  2019cites this paper
• Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis

  2019cites this paper
• A Review of Dysregulated Osteoblast and Osteoclast Coupling in Bone Disease and Failure

  2019cites this paper
• Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy

  2019cites this paper
• Manifestaciones reumatológicas de la infección por el virus de la inmunodeficiencia humana

  2013cites this paper